Why is Midostaurin not available in China?

Midostaurin (Midostaurin), as a kinase inhibitor targeting FLT3 gene mutations and other targets, has shown therapeutic efficacy in the treatment of acute myeloid leukemia (AML) and systemic mastocytosis (SM). However, despite its remarkable efficacy, midostaurin has not yet been launched in China, which is mainly affected by various factors.

The marketing of drugs in China must be approved by the State Food and Drug Administration. As a new anti-cancer drug, midostaurin requires the submission of a large amount of clinical trial data to prove its safety and effectiveness. During this process, R&D companies need to conduct clinical trials that meet the characteristics of the Chinese market. However, the lack of such trials may lead to a prolonged approval process or even failure to obtain approval. In addition, midostaurin's main indication is acute myeloid leukemia (AML). The incidence of this disease is relatively low, which may make it less attractive in the market and may affect the marketing decisions of pharmaceutical companies.

Market demand is also an important consideration. Although midostaurin has shown good efficacy in patients with FL3 mutation-positive AML, the overall treatment plan for acute myeloid leukemia in China still relies on traditional chemotherapy. Many hospitals and doctors may prefer to use existing chemotherapy drugs because they are more experienced and relatively low-cost. Therefore, market acceptance and demand for midostaurin, a new drug, may be limited.

In addition, the development and production of new drugs is expensive, especially for targeted drugs. Even if midostaurin can obtain marketing approval, its pricing strategy will be affected by medical insurance policies and market competition. In China, the prices of many targeted therapy drugs are generally high, and patients' affordability and medical insurance coverage restrict the actual use of the drugs.